脑电生物反馈联合艾司西酞普兰对精神分裂症患者的疗效观察  

Efficacy of electroencephalography biofeedback combined with escitalopram in patients with schizophrenia

作　　者：潘俊夫 周海腾 邵学克 PAN Junfu;ZHOU Haiteng;SHAO Xueke(Department of Memory Disorders,The Affiliated Kangning Hospital of Wenzhou Medical University(Zhejiang Provincial Clinical Research Center for Mental Health),Wenzhou 325000,Zhejiang Province,China)

机构地区：[1]温州医科大学附属康宁医院(浙江省精神心理卫生临床医学研究中心)记忆障碍科,浙江温州325000

出　　处：《药学前沿》2025年第2期251-257,共7页China Pharmacist

基　　金：温州市科研项目项目(Y20210765)。

摘　　要：目的探究脑电生物反馈与艾司西酞普兰联合治疗较单独治疗对精神分裂症患者认知功能及血炎症因子和神经因子水平的影响。方法选取2020年1至2022年3月于温州医科大学附属康宁医院接受诊治的精神分裂症患者临床资料实施回顾性分析,根据患者治疗方式不同分为艾司西酞普兰组(口服艾司西酞普兰进行治疗)、脑电生物反馈组(采用脑电生物反馈疗法进行治疗)和联合治疗组(采用脑电生物反馈疗法联合艾司西酞普兰进行治疗)。采用单因素方差分析比较3组患者临床总治疗有效情况、认知功能[简易精神状态检查量表(MMSE)、洛文斯顿认知功能评定测验(LOTCA)]、治疗前后的血清炎性因子指标[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-2(IL-2)]、神经因子指标[神经生长因子(NGF)、脑源性神经营养因子(BDNF)、胶质细胞源性神经营养因子(GDNF)]的差异,并观察不良反应发生情况。结果共收集到109例精神分裂症患者临床资料,其中艾司西酞普兰组36例,脑电生物反馈组36例,联合治疗组37例。相比于艾司西酞普兰组和脑电生物反馈组,联合治疗组治疗总有效率更高(P<0.05)。治疗后,3组患者的MMSE和LOTCA评分、NGF、BDNF、GDNF水平均显著升高,TNF-α、CRP、IL-2水平显著降低(P<0.05);与艾司西酞普兰组和脑电生物反馈组相比,联合治疗组的MMSE和LOTCA评分、NGF、BDNF、GDNF水平更高,TNF-α、CRP、IL-2水平更低(P<0.05)。3组患者的不良反应发生情况、总不良反应发生率比较差异均无统计学意义(P>0.05)。结论脑电生物反馈与艾司西酞普兰联合治疗较单独治疗疗效更显著,并能提升认知功能、改善精神分裂症患者的神经功能及抑制炎症反应。Objective To investigate the effects of combined electroencephalography(EEG)biofeedback and escitalopram treatment on cognitive function and blood inflammatory factor and neurotrophic factor levels in patients with schizophrenia compared to escitalopram treatment alone.Methods The clinical data of schizophrenia patients who received treatment in The Affiliated Kangning Hospital of Wenzhou Medical University from January 2020 to March 2022 were retrospectively analysed,and the patients were divided into the escitalopram group(treated with oral Escitalopram),the EEG biofeedback group(treated with EEG biofeedback therapy)and the combination therapy group(treated with EEG biofeedback therapy combined with Escitalopram)according to the different treatment regimens.One-way ANOVA analysis was used to compare the overall clinical treatment effectiveness and cognitive function[Mini-mental State Examination(MMSE)and Loewenstein Occupational Therapy Cognitive Assessment(LOTCA)]of three groups of patients,and the differences in serum inflammatory factor indicators[tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)and interleukin-2(IL-2)]and neurotrophic factor indicators[nerve growth factor(NGF),brain-derived neurotrophic factor(BDNF)nad glial cell derived neurotrophic factor(GDNF)]before and after treatment.The occurrence of adverse reactions were observed.Results Clinical data of a total of 109 patients with schizophrenia were collected,including 36 in the escitalopram group,36 in the EEG biofeedback group,and 37 in the combination therapy group.Compared with the escitalopram group and the EEG biofeedback group,the combination therapy group had a higher overall effective rate(P<0.05).After treatment,the scores of MMSE and LOTCA,and the levels of NGF,BDNF and GDNF significantly increased in all three groups of patients,while the levels of TNF-α,CRP and IL-2 significantly decreased(P<0.05);compared with the escitalopram group and the EEG biofeedback group,the combination therapy group had higher scores of MMSE and LOT

关 键 词：脑电生物反馈 艾司西酞普兰 精神分裂症 炎症因子 认知功能 

分 类 号：R749.3[医药卫生—神经病学与精神病学]